These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 17223743

  • 1. Alfimeprase: a novel recombinant direct-acting fibrinolytic.
    Deitcher SR, Funk WD, Buchanan J, Liu S, Levy MD, Toombs CF.
    Expert Opin Biol Ther; 2006 Dec; 6(12):1361-9. PubMed ID: 17223743
    [Abstract] [Full Text] [Related]

  • 2. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis.
    Toombs CF.
    Haemostasis; 2001 Dec; 31(3-6):141-7. PubMed ID: 11910179
    [Abstract] [Full Text] [Related]

  • 3. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase.
    Deitcher SR, Toombs CF.
    Pathophysiol Haemost Thromb; 2005 Dec; 34(4-5):215-20. PubMed ID: 16707931
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
    Shah AR, Scher L.
    IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
    Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR.
    J Clin Oncol; 2006 Jul 01; 24(19):3056-60. PubMed ID: 16809729
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR, Collen D.
    Thromb Haemost; 1995 Jul 01; 74(1):387-90. PubMed ID: 8578491
    [Abstract] [Full Text] [Related]

  • 10. Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase.
    Lee JY, Markland FS, Lucchesi BR.
    J Cardiovasc Pharmacol; 2013 Feb 01; 61(2):152-9. PubMed ID: 23188127
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. New directions in thrombolytic therapy.
    Toombs CF.
    Curr Opin Pharmacol; 2001 Apr 01; 1(2):164-8. PubMed ID: 11714091
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alfimeprase to succeed Genentech's alteplase?
    Vastag B.
    Nat Biotechnol; 2006 Aug 01; 24(8):875-6. PubMed ID: 16900112
    [No Abstract] [Full Text] [Related]

  • 19. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE, Davidson DJ, Lubbers NL, Reininger IM, Henkin J.
    Thromb Res; 1996 Sep 15; 83(6):421-31. PubMed ID: 8885137
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.